The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma

Blood

Volumn 117, Issue 8, 2011, Pages 2405-2413

  Rossi, Davide ^a   Rasi, Silvia ^a   Di Rocco, Alice ^b   Fabbri, Alberto ^c   Forconi, Francesco ^c   Gloghini, Annunziata ^d   Bruscaggin, Alessio ^a   Franceschetti, Silvia ^a   Fangazio, Marco ^a   De Paoli, Lorenzo ^a   Bruna, Riccardo ^a   Capello, Daniela ^a   Chiappella, Annalisa ^e   Bodoni, Chiara Lobetti ^f   Giachelia, Manuela ^g   Tisi, Maria Chiara ^g   Pogliani, Enrico M ^h   Lauria, Francesco ^c   Ladetto, Marco ^f   Hohaus, Stefan ^g   Martelli, Maurizio ^b   Vitolo, Umberto ^e   Carbone, Antonino ⁱ   Foá, Robin ^b   Gaidano, Gianluca ^a   more..

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e Azienda Ospedaliero Universitaria S Giovanni Battista   (Italy)

^f UNIVERSITY OF TURIN   (Italy)

^g CATHOLIC UNIVERSITY   (Italy)

^h UNIVERSITY OF MILANO BICOCCA   (Italy)

ⁱ CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; CONTROLLED STUDY; DNA REPAIR; FEMALE; GENOTOXICITY; GENOTYPE; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MISMATCH REPAIR; OVERALL SURVIVAL; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 79952149366     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-07-296244     Document Type: Article

References (50)

1. Swerdlow SH, Campo E, Harris NL, et al. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer; 2008.
2. International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329(14):987-994.
3. Abramson JS, Shipp MA. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood. 2005;106(4):1164-1174. (Pubitemid 41129574)
4. Lossos IS, Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(6):995-1007. (Pubitemid 46638855)
5. Cheung KJ, Horsman DE, Gascoyne RD. The significance of TP53 in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target. Br J Haematol. 2009;146(3):257-269.
6. Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med. 2010;362(15):1417-1429.
7. Lech-Maranda E, Baseggio L, Bienvenu J, et al. Interleukin-10 gene promoter polymorphisms in- fluence the clinical outcome of diffuse large B-cell lymphoma. Blood. 2004;103(9):3529-3534. (Pubitemid 38525688)
8. Habermann TM, Wang SS, Maurer MJ, et al. Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era. Blood. 2008;112(7):2694-2702.
9. Kube D, Hua TD, von Bonin F, et al. Effect of interleukin-10 gene polymorphisms on clinical outcome of patients with aggressive non-Hodgkin's lymphoma: an exploratory study. Clin Cancer Res. 2008;14(12):3777-3784.
10. Rossi D, Rasi S, Franceschetti S, et al. Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. Leukemia. 2009;23(6):1118-1126.
11. Schoof N, von Bonin F, Zeynalova S, et al. Favorable impact of the interleukin-4 receptor allelic variant I75 on the survival of diffuse large B-cell lymphoma patients demonstrated in a large prospective clinical trial. Ann Oncol. 2009;20(9): 1548-1554.
12. Kinsella TJ. Coordination of DNA mismatch repair and base excision repair processing of chemotherapy and radiation damage for targeting resistant cancers. Clin Cancer Res. 2009;15(6):1853-1859.
13. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res. 2008;14(5):1291-1295. (Pubitemid 351413906)
14. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009;461(7267):1071-1078.
15. Downs JA. Chromatin structure and DNA double-strand break responses in cancer progression and therapy. Oncogene. 2007;26(56):7765-7772. (Pubitemid 350242456)
16. egi ME, Sciuscio D, Murat A, Levivier M, Stupp R. Epigenetic deregulation of DNA repair and its potential for therapy. Clin Cancer Res. 2009;15(16): 5026-5031.
17. Fink D, Aebi S, Howell SB. The role of DNA mismatch repair in drug resistance. Clin Cancer Res. 1998;4(1):1-6. (Pubitemid 28062870)
18. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-242. (Pubitemid 34438862)
19. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005; 23(18):4117-4126. (Pubitemid 46211317)
20. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23(22):5027-5033. (Pubitemid 46224009)
21. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006; 24(19):3121-3127. (Pubitemid 46638950)
22. Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the Mab-Thera International Trial (MInT) Group. Lancet Oncol. 2006;7(5):379-391.
23. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9(2):105-116.
24. Vellenga E, van Putten WL, van't Veer MB, et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/ progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood. 2008; 111(2):537-543.
25. Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004;103(10):3684-3688. (Pubitemid 38596282)
26. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989; 78(11):1630-1636. (Pubitemid 19272832)
27. Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc. 1968;16(5):622-626.
28. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244-1253. (Pubitemid 29162950)
29. Mackay HJ, Cameron D, Rahilly M, et al. Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease-free survival. J Clin Oncol. 2000;18(1):87-93. (Pubitemid 30036340)
30. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohisto-chemistry using a tissue microarray. Blood. 2004; 103(1):275-282. (Pubitemid 38029949)
31. Carbone A, Gloghini A, Libra M, et al. A spindle cell variant of diffuse large B-cell lymphoma possesses genotypic and phenotypic markers characteristic of a germinal center B-cell origin. Mod Pathol. 2006;19(2):299-306. (Pubitemid 43117616)
32. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Am Stat Assoc. 1958;53:457-481.
33. Cox DR. Regression models and life tables. J R Stat Assoc. 1972;34:187-220.
34. Benjamini Y, Hochberg Y. Controlling false discovery rate: a practicable and powerful approach to multiple testing. J R Stat Soc B. 1995;57:289-300.
35. Curia MC, Palmirotta R, Aceto G, et al. Unbalanced germ-line expression of hMLH1 and hMSH2 alleles in hereditary nonpolyposis colorectal cancer. Cancer Res. 1999;59(15):3570-3575. (Pubitemid 29381854)
36. Kim JC, Roh SA, Koo KH, et al. Genotyping possible polymorphic variants of human mismatch repair genes in healthy Korean individuals and sporadic colorectal cancer patients. Fam Cancer. 2004;3(2):129-137. (Pubitemid 40645895)
37. Fink D, Nebel S, Aebi S, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res. 1996;56(21):4881-4886. (Pubitemid 26374423)
38. Aebi S, Fink D, Gordon R, et al. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin Cancer Res. 1997;3(10):1763-1767. (Pubitemid 27444715)
39. Fedier A, Schwarz VA, Walt H, Carpini RD, Haller U, Fink D. Resistance to topoisomerase poisons due to loss of DNA mismatch repair. Int J Cancer. 2001;93(4):571-576. (Pubitemid 32701417)
40. Mathonnet G, Krajinovic M, Labuda D, Sinnett D. Role of DNA mismatch repair genetic polymorphisms in the risk of childhood acute lymphoblastic leukaemia. Br J Haematol. 2003;123(1):45-48. (Pubitemid 37222756)
41. Bagnoli S, Putignano AL, Melean G, et al. Susceptibility to refractory ulcerative colitis is associated with polymorphism in the hMLH1 mismatch repair gene. Inflamm Bowel Dis. 2004;10(6):705-708. (Pubitemid 39545212)
42. Smith TR, Levine EA, Freimanis RI, et al. Polygenic model of DNA repair genetic polymorphisms in human breast cancer risk. Carcinogenesis. 2008;29(11):2132-2138.
43. Campbell PT, Curtin K, Ulrich CM, et al. Mismatch repair polymorphisms and risk of colon cancer, tumour microsatellite instability and interactions with lifestyle factors. Gut. 2009;58(5):661-667.
44. Nejda N, Iglesias D, Moreno Azcoita M, Medina Arana V, González-Aguilera JJ, Fernández-Peralta AM. A MLH1 polymorphism that increases cancer risk is associated with better outcome in sporadic colorectal cancer. Cancer Genet Cytogenet. 2009;193(2):71-77.
45. Vietri MT, Riegler G, De Paola M, et al. I219V polymorphism in hMLH1 gene in patients affected with ulcerative colitis. Genet Test Mol Biomarkers. 2009;13(2):193-197.
46. Langeberg WJ, Kwon EM, Koopmeiners JS, Ostrander EA, Stanford JL. Population-based study of the association of variants in mismatch repair genes with prostate cancer risk and outcomes. Cancer Epidemiol Biomarkers Prev. 2010;19(1):258-264.
47. Picelli S, Zajac P, Zhou XL, et al. Common variants in human CRC genes as low-risk alleles. Eur J Cancer. 2010;46(6):1041-1048.
48. Pfreundschuh M, Ho AD, Cavallin-Stahl E, et al. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol. 2008;9(5):435-444.
49. Pfreundschuh M. How I treat elderly patients with diffuse large B-cell lymphoma. Blood. 2010; 116(24):5103-5110.
50. Young KH, Leroy K, Møller MB, et al. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood. 2008; 112(8):3088-3098.